论文部分内容阅读
目的探讨缬沙坦联合阿托伐他汀应用于早期糖尿病肾病(DN)的治疗效果。方法 60例糖尿病肾病患者,按照随机分组法分为对照组和治疗组,每组30例。两组患者均采用常规治疗,在此基础上对照组采用缬沙坦治疗,治疗组则采用缬沙坦+阿托伐他汀治疗,两组患者疗程均为4个月。疗程结束后,将两组患者肾小球滤过率(GRF)、β2微球蛋白(β2-MG)、血清肌酐(Scr)、尿蛋白排泄率(UAER)以及头痛头晕、咳嗽等不良症状发生情况进行比较。结果治疗4个月后,治疗组患者的肾小球滤过率、β2微球蛋白、血清肌酐、尿蛋白排泄率分别为(147.2±20.5)ml/min、(46.5±14.1)μg/L、(70.2±9.3)μmol/L、(65.3±11.9)μg/min,明显优于对照组的(136.8±16.5)ml/min、(62.0±16.3)μg/L、(81.3±10.3)μmol/L、(86.9±15.3)μg/min,差异具有统计学意义(P<0.05)。两组患者药品不良情况发生率比较差异无统计学意义(P>0.05)。结论采用缬沙坦+阿托伐他汀治疗糖尿病肾病患者能够显著降低血清肾小球滤过率、血清肌酐、尿蛋白排泄率及β2微球蛋白水平,而且有效增强药品不良情况发生率,值得在临床治疗过程中大力推广使用。
Objective To investigate the therapeutic effect of valsartan combined with atorvastatin on early diabetic nephropathy (DN). Methods Sixty diabetic patients with diabetic nephropathy were randomly divided into control group and treatment group, 30 cases in each group. Two groups of patients were treated with conventional therapy, on the basis of the control group valsartan treatment, the treatment group was treated with valsartan + atorvastatin, two groups of patients were treated for 4 months. After treatment, glomerular filtration rate (GRF), β2 microglobulin (β2-MG), serum creatinine (Scr), urinary protein excretion rate (UAER) and headache, dizziness, cough and other adverse symptoms occurred The situation is compared. Results After 4 months of treatment, the GFR, β2 microglobulin, serum creatinine and urinary protein excretion rate in the treatment group were (147.2 ± 20.5) ml / min and (46.5 ± 14.1) μg / L respectively, (70.2 ± 9.3) μmol / L and (65.3 ± 11.9) μg / min respectively, which was significantly higher than that of the control group (136.8 ± 16.5) ml / min, , (86.9 ± 15.3) μg / min, the difference was statistically significant (P <0.05). Two groups of patients with adverse drug incidence was no significant difference (P> 0.05). Conclusion The treatment of diabetic nephropathy with valsartan and atorvastatin can significantly reduce the serum glomerular filtration rate, serum creatinine, urinary protein excretion rate and β2 microglobulin level, and effectively enhance the incidence of adverse drug reactions, it is worth Promote the use of clinical treatment process.